Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.49 |
| ▸ | KCNJ5 | P48544 | 6/20 | 0.48 |
| ▸ | KCNJ3 | P48549 | 6/20 | 0.48 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | KCNJ6 | P48051 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9926570 | 0.89 | SMN1; SMN2 (0.54) | CYP1A2CYP2C9CYP2C19KCNJ5KCNJ3 | |
| SCHEMBL9926589 | 0.87 | HPGD (0.57) | CYP1A2CYP2C19KCNJ5KCNJ3KCNJ6 | |
| SCHEMBL9926626 | 0.81 | P2RX7 (0.41) | KMT2A | |
| SCHEMBL9926557 | 0.79 | CXCL8 (0.41) | CYP2C9SMN1; SMN2PPARG | |
| SCHEMBL9926581 | 0.78 | CA1 (0.48) | ALDH1A1KDM4EMAPTAPEX1 | |
| SCHEMBL9926555 | 0.76 | MEP1B (0.41) | MEN1KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9926620 | 0.75 | HPGD (0.49) | KDM4ELMNAHSD17B10 | |
| SCHEMBL9926537 | 0.75 | KDM4E (0.54) | ALDH1A1KDM4E | |
| SCHEMBL9926575 | 0.75 | POLB (0.44) | KMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL10927020 | 0.75 | CYP1A2 (0.59) | CYP1A2CYP2D6CYP2C9CYP2C19KCNJ5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | NOVARTIS AG (CH) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149661-A1 | TETRA-SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR USE AS MDM2 AND/OR MDM4 MODULATORS | MDM4, MDM2, TP53 | CYP1A2 1912/4885CYP2D6 1204/4885CYP2C9 2619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.